RxDoctor Payments Data

Sankeerth Challagundla

Pain Medicine · Columbia, SCNPI 1861847766

Payments from drug & device makers

What this record shows

This record is dominated by grants: $10,162 of the $14,943 with a category attached, or 68.0%. Medtronic accounts for 83.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2021 at $10,639 and has fallen 99.3% since, to $79 in 2025. Among pain medicine clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,943in general payments, 2019–2025

Across 56 payments — averaging $266.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$13K
  • Abbott$901
  • Painteq LLC$200
  • Spinal Simplicity, LLC$198
  • SPR Therapeutics, Inc$145
  • Amgen$144
  • plus $836 from 12 others

What the payments were for

  • Grants$10,16268%
  • Travel & lodging$1,49110%
  • Food & beverage$3,25922%
  • Education$320%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,943 in reported general payments places this provider in the 90th percentile of 92 pain medicine providers in South Carolina.

See all pain medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$192,161
Medicare patients
262
Services billed
17,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant55$58,536
Nurtec OdtRimegepant Sulfate31$40,075
QuliptaAtogepant14$15,305
Aimovig AutoinjectorErenumab-Aooe15$11,127
Gabapentin222$3,195
Pregabalin45$3,188
Sumatriptan Succinate29$2,140
Carbamazepine ErCarbamazepine14$1,730
Tizanidine Hcl199$1,204
Duloxetine Hcl54$884
Oxcarbazepine22$781
Lamotrigine13$720
RizatriptanRizatriptan Benzoate38$562
Venlafaxine Hcl ErVenlafaxine Hcl42$526
Meloxicam204$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$68$73,84069 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 pain medicine providers in South Carolina.

Other pain medicine in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →